Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 78pembrolizumab 66Carboplatin 58Bevacizumab 58Specimen Handling 49Magnetic Resonance Spectroscopy 40Cisplatin 36olaparib 31Gemcitabine 27liposomal doxorubicin 25Biopsy 22Taxes 19Cyclophosphamide 18Topotecan 17Nivolumab 17Doxorubicin 16Immunoglobulin G 15niraparib 14Letrozole 14Disulfides 14lenvatinib 13fludarabine 13atezolizumab 12Surveys and Questionnaires 12Drug Therapy 12Radiotherapy 11Platinum 11abemaciclib 10Docetaxel 10Brachytherapy 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Poly(ADP-ribose) Polymerase Inhibitors × Gynecologic × 90 days × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡